Appropriate use of PCSK9 Inhibitors in India.

Anticholesteremic Agents Cholesterol, LDL Enzyme Inhibitors / therapeutic use India PCSK9 Inhibitors Proprotein Convertase 9 / metabolism

Journal

The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 18 7 2019
pubmed: 18 7 2019
medline: 4 9 2019
Statut: ppublish

Résumé

The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle changes, statins and ezetimibe effectively lower LDL-C and consequently improve CV outcomes. However, there are situations where these drugs fall short of achieving the target or they may not be well tolerated.

Identifiants

PMID: 31311223
pubmed: 31311223

Substances chimiques

Anticholesteremic Agents 0
Cholesterol, LDL 0
Enzyme Inhibitors 0
PCSK9 Inhibitors 0
PCSK9 protein, human EC 3.4.21.-
Proprotein Convertase 9 EC 3.4.21.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-85

Informations de copyright

© Journal of the Association of Physicians of India 2011.

Auteurs

S S Iyengar (SS)

Consultant Cardiologist, Manipal Hospital, Bangalore, Karnataka.

Manish Bansal (M)

Associate Director, Clinical and Preventive Cardiology , Heart Institute, Medanta Medicity, Gurgaon, Haryana.

Jps Sawhney (J)

Chairman, Deptt. of Cardiology Sir Ganga Ram Hospital, New Delhi.

Gurpreet Wander (G)

Professor & Chief Cardiologist, Hero DMC Heart Institute, Ludhiana, Punjab.

S N Narasingan (SN)

Managing Director, SNN Specialties Clinic, Alwarpet , Chennai, Tamil Nadu.

K Sarat Chandra (KS)

Consultant Cardiologist, Indo US Superspeciality Hospital, Hyderabad, Telangana.

Prabhakar D (P)

Senior Consultant Interventional Cardiologist, Ashwin Clinic, Dr.Mehta's Hospital, Apollo group of Hospitals, Chennai, Tamil Nadu.

Tiny Nair (T)

Associate Professor of Cardiology, Govt. Medical College, Thiruvananthapuram, Kerala.

B Krishnakumar (B)

Associate Professor of Cardiology, Govt. Medical College, Thiruvananthapuram, Kerala.

Nitin Deshpande (N)

Spandan Heart Institute Research Center, Dhantoli, Nagpur, Maharashtra.

Neil Bardoloi (N)

Managing Director and HOD, Cardiology, Guwahati, Assam.

Sadananda Shetty (S)

Cardiologist, Somaiya Superspeciality Hospital, Mumbai, Maharashtra.

Nagaraj Desai (N)

Cardiologist, Namana Medical Centre, Bangalore, Karnataka.

A K Pancholia (AK)

Physician and Cardiologist, Indore, Madhya Pradesh.

Ajay Swamy (A)

Sr. Advisor (Cardiology), Professor Department of Cardiology, MHCTC, Pune, Maharashtra.

Articles similaires

A retrospective analysis on optimal medical therapy for patients with symptomatic lower extremity peripheral artery disease: a French observational study.

Camille de Kermenguy, Anne Durand, Quentin Tollenaere et al.
1.00
Humans Peripheral Arterial Disease Retrospective Studies Male Female

Exploring transcriptomic mechanisms underlying pulmonary adaptation to diverse environments in Indian rams.

Ritika Gera, Reena Arora, Pooja Chhabra et al.
1.00
Animals Lung India Sheep Transcriptome

Environmental impact assessment of Flora and its role in offsetting carbon along National Highway-16, India.

H Ramamohan, S Raminaidu, I Sudhakara Rao et al.
1.00
India Carbon Sequestration Environmental Monitoring Carbon Biomass

Drug repurposing against fucosyltransferase-2 via docking, STD-NMR, and molecular dynamic simulation studies.

Muhammad Atif, Humaira Zafar, Atia-Tul- Wahab et al.
1.00
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Appropriate use of PCSK9 Inhibitors in India.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Lipoprotéines LDL › Cholestérol LDL › Appropriate use of PCSK9 Inhibitors in India.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Appropriate use of PCSK9 Inhibitors in India.
questionsmedicales.fr › Régions géographiques › Asie › Asie de l'Ouest › Asie du Sud › Inde › Appropriate use of PCSK9 Inhibitors in India.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Inhibiteurs de PCSK9 › Appropriate use of PCSK9 Inhibitors in India.
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Protéases à sérine › Serine endopeptidases › Proprotéine convertase 9 › Appropriate use of PCSK9 Inhibitors in India.